J Korean Ophthalmol Soc > Volume 50(8); 2009 > Article
Journal of the Korean Ophthalmological Society 2009;50(8):1197-1203.
DOI: https://doi.org/10.3341/jkos.2009.50.8.1197    Published online August 15, 2009.
Short-term Effect of Intravitreal Bevacizumab Injection Preventing Panretinal Photocoagulation-Induced Macular Edema in Proliferative Diabetic Retinopathy.
Jung Sub Kim, Ho Ra
Department of Ophthalmology, College of Medicine, The Catholic University of Korea, Seoul, Korea. raho@catholic.ac.kr
범망막광응고술 전 유리체내 베바시주맙 주입술의 황반부종 감소의 단기 효과
김정섭ㆍ나 호
Department of Ophthalmology, College of Medicine, The Catholic University of Korea, Seoul, Korea
Abstract
PURPOSE
To investigate the effect of intravitreal bevacizumab injection in preventing panretinal photocoagulation (PRP)-induced macular edema and visual dysfunction in proliferative diabetic retinopathy. METHODS: We conducted a prospective study of 40 consecutive eyes (20 patients) with proliferative diabetic retinopathy whose visual acuity (logMAR) was 0.2 or less, foveal thickness (microm) was 280 or less, and retinopathy was bilaterally symmetrical. In Group 1 (20 eyes), PRP was performed with intravitreal bevacizumab injection 1 week before the initiation of PRP, but in Group 2 (20 eyes) PRP alone was performed. In all eyes, PRP was completed using the same technique. Best corrected visual acuity (BCVA) and foveal and parafoveal thicknesses were measured before treatment and 1 and 3 months after PRP. RESULTS: Before treatment, the mean BCVA and foveal and parafoveal thicknesses were not statistically significantly different between the two groups (p>0.05). At 1 and 3 months after PRP, the mean BCVA improved and the foveal and parafoveal thicknesses were significantly smaller in Group 1 than in Group 2 (p<0.05). CONCLUSIONS: Intravitreal bevacizumab injection before PRP could help prevent PRP-induced macular edema and visual dysfunction in patients with proliferative diabetic retinopathy and good vision.
Key Words: Bevacizumab;Macular edema;Panretinal photocoagulation;Proliferative diabetic retinopathy


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next